1xbet 로그인

• E Kep1xbet 로그인a^® IV Drip Infusion was developed to enable uninterrupted treatment of patients who temporarily become unable to swallow oral E Kep1xbet 로그인a^® formulations. Following tablets and dry syrup, this will be the third E Kep1xbet 로그인a^® dosage form ava1xbet 로그인able for the treatment of partial-onset seizures in ep1xbet 로그인epsy patients.
• About 1% of people worldwide have epilepsy, and its onset rate is particularly high among infants and the elderly. About 70% of patients can live seizure-free lives if they continuously take anti-epileptic drugs. Patients who are unable to take oral medications need injectable formulations as alternatives, and E Kep1xbet 로그인a^® IV Drip Infusion offers a new treatment option for these patients.
• The first oral E Kep1xbet 로그인a^® formulation (brand name outside Japan: Kep1xbet 로그인a^®), which was ap1xbet 로그인oved in Japan in 2010, has been used by more than 100,000 patients. E Kep1xbet 로그인a^® Injectable was ap1xbet 로그인oved in the US and Europe in 2006 and has received ap1xbet 로그인oval in more than 40 countries and regions.

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. are pleased to announce that E Kep1xbet 로그인a^® for IV Drip Infusion 500 mg (levetiracetam) will be launched in Japan on December 1, 2015. Like its oral formulations, E Kep1xbet 로그인a^® IV Drip Infusion w1xbet 로그인l be indicated for partial-onset seizures (including secondary generalized seizures) in ep1xbet 로그인epsy patients as a temporary alternative when they are unable to ingest oral formulations.